CO5290257A1 - Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia - Google Patents

Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia

Info

Publication number
CO5290257A1
CO5290257A1 CO01013432A CO01013432A CO5290257A1 CO 5290257 A1 CO5290257 A1 CO 5290257A1 CO 01013432 A CO01013432 A CO 01013432A CO 01013432 A CO01013432 A CO 01013432A CO 5290257 A1 CO5290257 A1 CO 5290257A1
Authority
CO
Colombia
Prior art keywords
alkyl
alkoxy
optionally substituted
phenyl
halogen
Prior art date
Application number
CO01013432A
Other languages
English (en)
Inventor
Tim Birkinshaw
David Cheshire
Antonio Mete
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5290257A1 publication Critical patent/CO5290257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de la fórmula (I)<EMI FILE="01013432_1" ID="1" IMF=JPEG >En donde X y Y independientemente representan alquil C1 a 4, alcoxi C1 a 4, halógeno, CF3, OCF3, CN, C=CH, S(O)mCH3, S(O)pCF3, NO2 o NHCHO,m y p independientemente representan un entero 0, 1 o 2;Z representa H o fluoro;V representa O, S(O)n o NR3; W representa alquil C1 a 4, alquenil C2 a 4, alquinil C2 a 4, cicloalquil C3 a 6 o un anillo heterociclico saturado de 4 a 8 miembros que incorpora un heteroátomo seleccionado entre O, S y N; cualquiera de dichos grupos siendo además opcionalmente substituido por alquil C1 a 4, alcoxi C1 a 4, alquiltio C1 a 4, cicloalquil C3 a 6, halógeno o fenil; dicho grupo fenil siendo opcionalmente substituido además por uno o más substituyentes seleccionados independientemente entre halógeno, alquil C1 a 4, alcoxi C1 a 4, CF3, OCF3, CN o NO2;o W representa fenil o un anillo heterocíclico aromático de cinco o seis miembros que contiene 1 a 3 heteroátomos independientemente seleccionados entre O, S y N; dicho fenil o anillo heterocíclico aromático siendo opcionalmente substituido por uno o más substituyentes seleccionados independientemente entre halógeno, alquil C1 a 4, alcoxi C1 a C4, OH, CN, NO2 o NR4R5; dicho grupo alquil o alcoxi siendo además opcionalmente substituido por uno o más átomos de flúor;R1 y R2 independientemente representan H, alquil C1 a 4 o cicloalquil C3 a 6; dicho grupo alquil siendo opcionalmente substituido por alcoxi C1 a 4, halógeno, hidroxi, NR6R7, fenil o un anillo heterocíclico saturado o aromático de cinco o seis miembros que contiene 1 a 3 heteroátomos independientemente seleccionados entre O, S y N; - 2 -dicho fenil o anillo heterocíclico aromático siendo además opcionalmente substituido por halógeno, alquil C1 a 4, alcoxi C1 a 4, CF3, OCF3, CN o NO2;o el grupo NR1R2 junto representa un anillo azacíclico saturado de 4 a 8 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S o NR8; dicho anillo siendo opcionalmente substituido por alquil C1 a 4, alcoxi C1 a 4 o OH; dicho grupo alquil siendo opcionalmente substituido por alcoxi C1 a 4, OH o NR9R10; o el grupo NR1R2 junto representa parte de un anillo azacíclico aromático de cinco miembros que incorpora opcionalmente un átomo N adicional;R3 representa H o alquil C1 a 4;R4, R5, R6, R7, R9 y R10 independiente representan H o alquil C1 a 4;R8 representa H o alquil C1 a 6; dicho grupo alquil siendo opcionalmente substituido por alcoxi C1 a 4, OH, NR11R12, fenil o un anillo heterocíclico saturado o aromático de cinco a seis miembros que contiene 1 a 3 heteroátomos independientemente seleccionados entre O, S y N; dicho fenil o anillo heterocíclico aromático siendo además opcionalmente substituido por halógeno, alquil C1 a 4, alcoxi C1 a 4, CF3, OCF3, CN o NO2; R11 y R12 independientemente representan H o alquil C1 a 4;n representa un entero 0, 1 o 2;o una sal, enantiómero o racemato del mismo farmacéuticamente aceptable.
CO01013432A 2000-02-23 2001-02-20 Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia CO5290257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0004149.1A GB0004149D0 (en) 2000-02-23 2000-02-23 Novel compounds

Publications (1)

Publication Number Publication Date
CO5290257A1 true CO5290257A1 (es) 2003-06-27

Family

ID=9886161

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01013432A CO5290257A1 (es) 2000-02-23 2001-02-20 Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia

Country Status (10)

Country Link
US (1) US6743939B2 (es)
EP (1) EP1263714B1 (es)
JP (1) JP2003523992A (es)
AR (1) AR028220A1 (es)
AT (1) ATE265422T1 (es)
AU (1) AU2001234313A1 (es)
CO (1) CO5290257A1 (es)
DE (1) DE60103033T2 (es)
GB (1) GB0004149D0 (es)
WO (1) WO2001062713A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0202279D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel comppounds
SE0202280D0 (sv) 2002-07-19 2002-07-19 Astrazeneca Ab Novel compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
EP2027087A2 (en) 2006-05-18 2009-02-25 MannKind Corporation Intracellular kinase inhibitors
DE102006031813B4 (de) * 2006-07-07 2011-04-28 Christian-Albrechts-Universität Zu Kiel Verwendung basischer Acetophenone als Hemmstoffe von NO-Synthasen
CA2898610C (en) 2013-01-21 2021-01-19 Osaka University Phenoxyalkylamine compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5144934B1 (es) * 1969-12-09 1976-12-01
JPS52941B1 (es) * 1969-12-09 1977-01-11
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5320825A (en) 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
EP0576766A1 (en) 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamine derivatives, their preparation and use
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000125A (es) 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
SK17912000A3 (sk) * 1998-06-03 2001-09-11 Pfizer Products Inc. 2-aminopyridny obsahujce kondenzovan cyklick substituenty ako inhibtory syntzy oxidu dusnatho

Also Published As

Publication number Publication date
AR028220A1 (es) 2003-04-30
DE60103033T2 (de) 2005-04-28
ATE265422T1 (de) 2004-05-15
GB0004149D0 (en) 2000-04-12
WO2001062713A1 (en) 2001-08-30
EP1263714A1 (en) 2002-12-11
EP1263714B1 (en) 2004-04-28
US20030105161A1 (en) 2003-06-05
DE60103033D1 (de) 2004-06-03
US6743939B2 (en) 2004-06-01
AU2001234313A1 (en) 2001-09-03
JP2003523992A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
CO5261625A1 (es) Novedoso derivados fenilheteroalquilamina, procesos para su prepraracion, coposiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
CO5290257A1 (es) Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
CO5280046A1 (es) Agonistas alfa 7 y sus composiciones farmaceuticas
AR058614A1 (es) Compuesto de azaindol , composicion que lo comprende y su uso para preparar un medicamento
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
DE60320012D1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PE20060457A1 (es) Derivados de difenil eter como antagonistas de los receptores 5ht2
TW200633996A (en) N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine derivatives, preparation thereof and therapeutic use thereof
SE9703375D0 (sv) A new combination
UY27979A1 (es) Indoles sustituidos en posición 2,4
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
DK0686142T3 (da) Polyaminderivater som radioprotektive midler
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN

Legal Events

Date Code Title Description
FA Application withdrawn